Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Other Operating Expenses (2019 - 2025)

Inmune Bio's Other Operating Expenses history spans 7 years, with the latest figure at $16.5 million for Q2 2025.

  • For Q2 2025, Other Operating Expenses rose 13777.31% year-over-year to $16.5 million; the TTM value through Sep 2025 reached $16.5 million, up 14777.48%, while the annual FY2022 figure was -$1.3 million, 13.56% down from the prior year.
  • Other Operating Expenses for Q2 2025 was $16.5 million at Inmune Bio, up from $119000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $16.5 million in Q2 2025 and bottomed at -$425000.0 in Q1 2022.
  • The 5-year median for Other Operating Expenses is -$8000.0 (2021), against an average of $2.3 million.
  • The largest annual shift saw Other Operating Expenses plummeted 5212.5% in 2022 before it surged 13777.31% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at -$8000.0 in 2021, then tumbled by 5212.5% to -$425000.0 in 2022, then surged by 78.82% to -$90000.0 in 2023, then surged by 232.22% to $119000.0 in 2024, then soared by 13777.31% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Other Operating Expenses are $16.5 million (Q2 2025), $119000.0 (Q2 2024), and -$8000.0 (Q1 2024).